LGI1 tumor tissue expression and serum autoantibodies in patients with primary malignant glioma.
Clin Neurol Neurosurg
; 170: 27-33, 2018 07.
Article
em En
| MEDLINE
| ID: mdl-29723732
ABSTRACT
OBJECTIVES:
The Leucine-rich glioma inactivated 1 (LGI1) protein is thought to be implicated in malignant progression of glioma tumors, and mutations in the encoding gene, LGI1, cause autosomal dominant lateral temporal epilepsy, a genetic focal epilepsy syndrome. The aim of this study was to investigate the possible involvement of LGI1 in high-grade glioma-associated epilepsy by analyzing its expression in tumor specimens of patients with and without epilepsy and by searching for LGI1 autoantibodies in the sera these patients. PATIENTS ANDMETHODS:
We examined tumor tissue samples from 24 patients with high-grade gliomas (12 with and 12 without epilepsy) by immunoblot and detected variable amounts of LGI1 in tumor tissues from 9/24 (37%) patients.RESULTS:
LGI1 was detected in 7/12 (58%) patients with epilepsy and in 2/12 (16%) patients without epilepsy (pâ¯=â¯0.0894; Fisher's exact test). Moreover, testing blood sera of five patients for antibodies against LGI1 revealed LGI1 autoantibodies in two patients, both suffering from epilepsy and expressing LGI1 in tumor tissue.CONCLUSION:
Our findings suggest that there may be a preferential expression of LGI1 in high-grade glioma tumors of patients with epilepsy. We also unveil the presence of serum LGI1 autoantibodies in some patients with high-grade gliomas, where they might play an epileptogenic role.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Astrocitoma
/
Autoanticorpos
/
Neoplasias Encefálicas
/
Proteínas
/
Glioblastoma
/
Epilepsia do Lobo Temporal
Idioma:
En
Ano de publicação:
2018
Tipo de documento:
Article